VYNE Therapeutics Inc (VYNE) Stock: A SWOT Analysis

7d ago, source: newsheater

Company’s 36-month beta value is 1.25.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.” The public float for VYNE is ...

Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now

1mon ago, source: Hosted on MSN

T he price trend for VYNE Therapeutics Inc. (VYNE) has been bearish lately and the stock has lost 6.7% over the past week. However, the formation of a hammer chart pattern in its last trading ...

VYNE Therapeutics Inc

5mon ago, source: CNN

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial ...

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

1mon ago, source: Business Insider

About VYNE Therapeutics Inc. VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory ...

VYNE Therapeutics Inc. (VYNE) Interactive Stock Chart - Yahoo Finance

1mon ago, source: Yahoo Finance

BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical ...

VYNE Therapeutics Inc VYNE

7d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

VYNE Therapeutics Inc.

22d ago, source: TheStreet.com

VYNE THERAPEUTICS INC's gross profit margin for the fourth quarter of its fiscal year 2023 is essentially unchanged when compared to the same period a year ago. The company grew its sales and net ...

VYNE Therapeutics Inc

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

VYNE Therapeutics Inc.

22d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...